Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
Hepatitis B Virus Genotypes in Patients with Hepatitis D as Determined by the Panel of Their Own Development of Monoclonal Antibodies. / Bezuglova, L. V.; Isaeva, O. V.; Karlsen, A. A. и др.
в: Molecular Genetics, Microbiology and Virology, Том 37, № 2, 06.2022, стр. 91-98.Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
}
TY - JOUR
T1 - Hepatitis B Virus Genotypes in Patients with Hepatitis D as Determined by the Panel of Their Own Development of Monoclonal Antibodies
AU - Bezuglova, L. V.
AU - Isaeva, O. V.
AU - Karlsen, A. A.
AU - Ilchenko, L. Y.
AU - Sleptsova, S. S.
AU - Saryglar, A. A.
AU - Poryvaeva, V. A.
AU - Mosina, Ya D.
AU - Agafonova, O. A.
AU - Mogilnykh, A. K.
AU - Kyuregyan, K. K.
AU - Mikhailov, M. I.
AU - Netesov, S. V.
AU - Netesova, I. G.
N1 - Funding Information: Thos work was financially supported by АО Vector-Best, as well as partially supported by an FSUS-2020-0035 grant for basic research of Novosibirsk State University and the TOP-100 Russian Universities Competitiveness Improvement Program. Publisher Copyright: © 2022, Allerton Press, Inc.
PY - 2022/6
Y1 - 2022/6
N2 - Direct genotyping of hepatitis B virus (HBV) in samples from patients with hepatitis delta can be impossible due to an undetectable concentration of HBV DNA. A sufficient amount of surface HBV protein (HBsAg) in such samples makes it possible to determine HBV genotype using enzyme-linked immunosorbent assay (ELISA) of this antigen with a panel of monoclonal antibodies (MABs). The purpose of this paper is to compare the results of HBV genotyping using an in-house MAB panel with the results of molecular analysis of samples from patients with chronic hepatitis B (CHB) and the determination of HBV genotypes in samples from patients with hepatitis delta. A total of 122 serum samples from CHB patients from Yakutia and 211 serum samples from hepatitis delta patients from Yakutia (12 samples) and Tuva (199 samples) were collected. HBV serotypes/genotypes were determined by ELISA using developed reagents. The molecular methods included the isolation of HBV DNA, amplification of the S gene region (713 nt), and phylogenetic analysis of the nucleotide sequences. In a group of samples from CHB patients positive for HBV DNA (86 samples), 95% (82/86) valid results were obtained using our MAB kit. The following genotypes were identified: A, 32 (39%); C, 3 (4%); and D, 47 (57%). The results of HBV genotyping using two methods were identical for 81/82 (99%) samples. HBV genotyping using developed reagents provided 96.2% (203/211) of valid results in samples from patients with hepatitis delta compared to 3.8% of such results obtained using the standard molecular technic (p < 0.001). The following HBV genotypes were identified: A, 17 samples (8.4%), and D, 186 samples (91.6%). The developed test with MAB panel allows one to reliably determine HBV genotype and has advantages over standard molecular methods for HBV genotyping in patients with hepatitis delta.
AB - Direct genotyping of hepatitis B virus (HBV) in samples from patients with hepatitis delta can be impossible due to an undetectable concentration of HBV DNA. A sufficient amount of surface HBV protein (HBsAg) in such samples makes it possible to determine HBV genotype using enzyme-linked immunosorbent assay (ELISA) of this antigen with a panel of monoclonal antibodies (MABs). The purpose of this paper is to compare the results of HBV genotyping using an in-house MAB panel with the results of molecular analysis of samples from patients with chronic hepatitis B (CHB) and the determination of HBV genotypes in samples from patients with hepatitis delta. A total of 122 serum samples from CHB patients from Yakutia and 211 serum samples from hepatitis delta patients from Yakutia (12 samples) and Tuva (199 samples) were collected. HBV serotypes/genotypes were determined by ELISA using developed reagents. The molecular methods included the isolation of HBV DNA, amplification of the S gene region (713 nt), and phylogenetic analysis of the nucleotide sequences. In a group of samples from CHB patients positive for HBV DNA (86 samples), 95% (82/86) valid results were obtained using our MAB kit. The following genotypes were identified: A, 32 (39%); C, 3 (4%); and D, 47 (57%). The results of HBV genotyping using two methods were identical for 81/82 (99%) samples. HBV genotyping using developed reagents provided 96.2% (203/211) of valid results in samples from patients with hepatitis delta compared to 3.8% of such results obtained using the standard molecular technic (p < 0.001). The following HBV genotypes were identified: A, 17 samples (8.4%), and D, 186 samples (91.6%). The developed test with MAB panel allows one to reliably determine HBV genotype and has advantages over standard molecular methods for HBV genotyping in patients with hepatitis delta.
KW - enzyme-linked immunosorbent assay
KW - genotype
KW - HBsAg
KW - hepatitis B virus
KW - hepatitis D
KW - monoclonal antibodies
UR - http://www.scopus.com/inward/record.url?scp=85139235647&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/fe79b94c-b934-324d-a8b6-fa0f1390bbe9/
U2 - 10.3103/S0891416822020033
DO - 10.3103/S0891416822020033
M3 - Article
AN - SCOPUS:85139235647
VL - 37
SP - 91
EP - 98
JO - Molecular Genetics, Microbiology and Virology
JF - Molecular Genetics, Microbiology and Virology
SN - 0891-4168
IS - 2
ER -
ID: 38159435